Sarosh Rana to Risk Assessment
This is a "connection" page, showing publications Sarosh Rana has written about Risk Assessment.
Connection Strength
0.790
-
Neonatal cost savings in hypertensive disorders of pregnancy: Economic evaluation of the sFlt-1/PlGF test with real world implementation of biomarkers. Pregnancy Hypertens. 2025 Mar; 39:101190.
Score: 0.130
-
Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2025 Apr; 232(4):385.e1-385.e21.
Score: 0.125
-
Angiogenic Biomarkers for Preeclampsia in Clinical Setting: A New Era. Hypertension. 2023 10; 80(10):2029-2032.
Score: 0.118
-
Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia. Clin Chem. 2022 06 01; 68(6):771-781.
Score: 0.108
-
Cost effectiveness of the sFlt1/PlGF ratio test as an adjunct to the current practice of evaluating suspected preeclampsia in the United States. Pregnancy Hypertens. 2021 Dec; 26:121-126.
Score: 0.104
-
Evaluation of angiogenic factors in the decision to admit women with suspected preeclampsia. Pregnancy Hypertens. 2020 Jul; 21:124-131.
Score: 0.094
-
Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenat Diagn. 2015 Apr; 35(4):386-93.
Score: 0.065
-
Impact of PlGF immunoassay imprecision on preeclampsia risk assessment with the sFlt-1 to PlGF ratio. Am J Clin Pathol. 2025 Aug 26; 164(2):200-206.
Score: 0.034
-
First trimester vitamin D, vitamin D binding protein, and subsequent preeclampsia. Hypertension. 2010 Oct; 56(4):758-63.
Score: 0.012